The Value of International Staging System in Predicting Survival of Multiple Myeloma Patients With Renal Failure

Yıl 2020, Cilt: 47 Sayı: 2, 237 - 242, 17.06.2020

Tuğçe Nur Yiğenoğlu Semih Başcı Mehmet Bakırtaş

https://doi.org/10.5798/dicletip.748566

Öz

Objectives: At the time of diagnosis, 20 to 30% of multiple myeloma (MM) patients have renal failure. International Staging System (ISS) is based on 2 variables: serum levels of albumin and beta 2-microglobulin (B2M). Serum B2M level increases in patients with renal failure. This means that the elevated serum level of B2M is not always correlated with tumor burden in MM patients who have renal failure. Therefore, these patients may have further ISS stages than they really have. In this study, we aim to evaluate the success of ISS in predicting survival in MM patients with renal failure.
Method: The data of 172 MM patients that underwent autologous stem cell transplantation (ASCT) at our center were retrospectively analyzed. The patients were divided into 5 renal function stages according to the Renal Disease Quality Classification of the National Kidney Foundation.
Results: Overall survival (OS) after ASCT was found 21 months in ISS1 patients, 20 months in ISS2 patients, and 18 months in ISS3 patients. OS in stage 0-1 patients was 18 months, it was 30 months in stage 2-3-4-5 patients. There was no statistically significant difference regarding OS between patients with renal failure and normal renal function in all ISS stages.
Conclusion: Our data reveals that the significance of ISS to predict overall survival is independent from renal failure.

Anahtar Kelimeler

Multipl myeloma

Kaynakça

• 1. Rajkumar V. Multiple Myeloma. Curr Probl Cancer 2009; 33: 7–64.
• 2. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–20.
• 3. Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009; 23: 1152–7.
• 4. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–20.